tetano
Editor, Senior Moderator
Curr Pharm Des
. 2022 Oct 20.
doi: 10.2174/1381612829666221020154246. Online ahead of print.
Vaccination against SARS-CoV-2 protects from COVID-19-induced endothelial dysfunction
Evangelos Oikonomou[SUP] 1 2 [/SUP], Stamatios Lampsas[SUP] 1 [/SUP], Nektarios Souvaliotis[SUP] 1 [/SUP], Savvas Sarantos[SUP] 1 [/SUP], Gerasimos Siasos[SUP] 1 2 3 [/SUP], Garyphallia Poulakou[SUP] 4 [/SUP], Thekla Lytra[SUP] 1 [/SUP], Georgios Angelos Papamikroulis[SUP] 1 [/SUP], Nikolaos Fountoulakis[SUP] 4 [/SUP], Panagiotis Theofilis[SUP] 2 [/SUP], Dimitris Tousoulis[SUP] 2 [/SUP], Manolis Vavuranakis[SUP] 1 [/SUP], Aikaterini Tsatsaragkou[SUP] 1 [/SUP], Georgios Marinos[SUP] 2 [/SUP], Dimitris Tousoulis[SUP] 2 [/SUP], Manolis Vavuranakis[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Coronavirus Disease-19 (COVID-19) is implicated in endotheliitis which adversely affects cardiovascular events. The impact of vaccination with COVID-19 on the clinical outcome of patients is documented.
Objective: To evaluate the impact of vaccination with COVID-19 on severe acute respiratory syndrome, coronavirus-2 (SARS-CoV-2) infection-related endothelial impairment.
Methods: We enrolled 45 patients hospitalized for COVID-19 (either vaccinated or not against SARS-CoV-2). Clinical and laboratory data were collected, and brachial artery flow-mediated dilation (FMD) was evaluated. Subjects without COVID-19 were used as the control group.
Results: There was no difference in age (64.7±7.5 years vs. 61.2±11.1 years vs. 62.4±9.5, p=0.28) and male sex (49% vs. 60% vs. 52%, p=0.71), between control subjects, vaccinated, and unvaccinated subjects with COVID-19 respectively. Of the patients with COVID-19, 44% were vaccinated against SARS-CoV-2. Unvaccinated COVID-19 patients had significantly impaired FMD compared to vaccinated COVID-19 patients and to Control subjects (2.05±2.41 % vs. 7.24±2.52 % vs. 7.36±2.94 %, p<0.001). Importantly, post hoc tests revealed that unvaccinated COVID-19 patients had significantly impaired FMD from both Vaccinated COVID-19 subjects (p<0.001) and form Control subjects (p<0.001). There was no difference in FMD between the control group and the vaccinated COVID-19 group (p=0.99).
Conclusion: Hospitalized patients with COVID-19 present endothelial dysfunction in the acute phase of the disease. Endothelial function in unvaccinated patients with COVID-19 is impaired compared to control subjects as well compared to vaccinated patients with COVID-19. Vaccinated hospitalized subjects with COVID-19 do not show endothelial dysfunction, strengthening the protective role of vaccination against SARS-CoV-2.
Keywords: COVID-19; SARS-CoV-2.; endothelial function; endotheliitis; flow-mediated dilation; vaccination.
. 2022 Oct 20.
doi: 10.2174/1381612829666221020154246. Online ahead of print.
Vaccination against SARS-CoV-2 protects from COVID-19-induced endothelial dysfunction
Evangelos Oikonomou[SUP] 1 2 [/SUP], Stamatios Lampsas[SUP] 1 [/SUP], Nektarios Souvaliotis[SUP] 1 [/SUP], Savvas Sarantos[SUP] 1 [/SUP], Gerasimos Siasos[SUP] 1 2 3 [/SUP], Garyphallia Poulakou[SUP] 4 [/SUP], Thekla Lytra[SUP] 1 [/SUP], Georgios Angelos Papamikroulis[SUP] 1 [/SUP], Nikolaos Fountoulakis[SUP] 4 [/SUP], Panagiotis Theofilis[SUP] 2 [/SUP], Dimitris Tousoulis[SUP] 2 [/SUP], Manolis Vavuranakis[SUP] 1 [/SUP], Aikaterini Tsatsaragkou[SUP] 1 [/SUP], Georgios Marinos[SUP] 2 [/SUP], Dimitris Tousoulis[SUP] 2 [/SUP], Manolis Vavuranakis[SUP] 1 [/SUP]
Affiliations
- PMID: 36278445
- DOI: 10.2174/1381612829666221020154246
Abstract
Background: Coronavirus Disease-19 (COVID-19) is implicated in endotheliitis which adversely affects cardiovascular events. The impact of vaccination with COVID-19 on the clinical outcome of patients is documented.
Objective: To evaluate the impact of vaccination with COVID-19 on severe acute respiratory syndrome, coronavirus-2 (SARS-CoV-2) infection-related endothelial impairment.
Methods: We enrolled 45 patients hospitalized for COVID-19 (either vaccinated or not against SARS-CoV-2). Clinical and laboratory data were collected, and brachial artery flow-mediated dilation (FMD) was evaluated. Subjects without COVID-19 were used as the control group.
Results: There was no difference in age (64.7±7.5 years vs. 61.2±11.1 years vs. 62.4±9.5, p=0.28) and male sex (49% vs. 60% vs. 52%, p=0.71), between control subjects, vaccinated, and unvaccinated subjects with COVID-19 respectively. Of the patients with COVID-19, 44% were vaccinated against SARS-CoV-2. Unvaccinated COVID-19 patients had significantly impaired FMD compared to vaccinated COVID-19 patients and to Control subjects (2.05±2.41 % vs. 7.24±2.52 % vs. 7.36±2.94 %, p<0.001). Importantly, post hoc tests revealed that unvaccinated COVID-19 patients had significantly impaired FMD from both Vaccinated COVID-19 subjects (p<0.001) and form Control subjects (p<0.001). There was no difference in FMD between the control group and the vaccinated COVID-19 group (p=0.99).
Conclusion: Hospitalized patients with COVID-19 present endothelial dysfunction in the acute phase of the disease. Endothelial function in unvaccinated patients with COVID-19 is impaired compared to control subjects as well compared to vaccinated patients with COVID-19. Vaccinated hospitalized subjects with COVID-19 do not show endothelial dysfunction, strengthening the protective role of vaccination against SARS-CoV-2.
Keywords: COVID-19; SARS-CoV-2.; endothelial function; endotheliitis; flow-mediated dilation; vaccination.